Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

被引：31

作者：

Adashek, Jacob J. ^{[1
]}

Menta, Arjun K. ^{[2
]}

Reddy, Neha K. ^{[3
]}

Desai, Aakash P. ^{[4
]}

Roszik, Jason ^{[5
]}

Subbiah, Vivek ^{[5
,6
,7
]}

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33620 USA

[2] Johns Hopkins Sch Med, Baltimore, MD USA

[3] Univ Texas Austin, Dept Internal Med, Sch Med, Austin, TX 78712 USA

[4] Mayo Clin, Div Med Oncol, Dept Med, Rochester, MN USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA

[7] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX 77030 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2022年 / 21卷 / 06期

关键词：

ERDHEIM-CHESTER DISEASE; CELL LUNG-CANCER; ANAPLASTIC THYROID-CARCINOMA; OPEN-LABEL; SINGLE-ARM; B-RAF; DABRAFENIB; VEMURAFENIB; TRAMETINIB; PHASE-2;

D O I：

10.1158/1535-7163.MCT-21-0950

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BRAF plus MEK inhibitor combinations are currently FDAapproved for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600-mutated colorectal cancer has prevented its tissueagnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation-positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malig-nancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.

引用

页码：871 / 878

页数：8

共 61 条

[1] From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm [J].

Adashek, Jacob J. ;

Subbiah, Vivek ;

Kurzrock, Razelle .

TRENDS IN CANCER, 2021, 7 (01) :15-28

[2] Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer [J].

Adashek, Jacob J. ;

Arroyo-Martinez, Yadis ;

Menta, Arjun K. ;

Kurzrock, Razelle ;

Kato, Shumei .

FRONTIERS IN ONCOLOGY, 2020, 10

[3] Transcriptomic silencing as a potential mechanism of treatment resistance [J].

Adashek, Jacob J. ;

Kato, Shumei ;

Parulkar, Rahul ;

Szeto, Christopher W. ;

Sanborn, J. Zachary ;

Vaske, Charles J. ;

Benz, Stephen C. ;

Reddy, Sandeep K. ;

Kurzrock, Razelle .

JCI INSIGHT, 2020, 5 (11)

[4]

Al Bayati Ahmed, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P303, DOI 10.1016/j.mayocpiqo.2018.05.001

[5] Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib [J].

Ali, Siraj M. ;

He, Je ;

Carson, Wade ;

Stephens, Phil J. ;

Fiorillo, Joseph ;

Lipson, Doron ;

Palmer, Gary A. ;

Ross, Jeffrey S. ;

Miller, Vincent A. ;

Sharman, Jeffrey .

CASE REPORTS IN ONCOLOGY, 2014, 7 (02) :343-348

[6] Single-agent dabrafenib for BRAFV600E-mutated histiocytosis [J].

Bhatia, Ankush ;

Ulaner, Gary ;

Rampal, Raajit ;

Hyman, David M. ;

Abdel-Wahab, Omar ;

Durham, Benjamin H. ;

Dogan, Ahmet ;

Ozkaya, Neval ;

Lacouture, Mario E. ;

Hajdenberg, Julio ;

Ganzel, Chezi ;

Diamond, Eli L. .

HAEMATOLOGICA, 2018, 103 (04) :E177-E180

[7] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[8] Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial [J].

Brose, Marcia S. ;

Cabanillas, Maria E. ;

Cohen, Ezra E. W. ;

Wirth, Lori J. ;

Riehl, Todd ;

Yue, Huibin ;

Sherman, Steven I. ;

Sherman, Eric J. .

LANCET ONCOLOGY, 2016, 17 (09) :1272-1282

[9] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[10] Analysis of the genome to personalize therapy for melanoma [J].

Davies, M. A. ;

Samuels, Y. .

ONCOGENE, 2010, 29 (41) :5545-5555

← 1 2 3 4 5 6 7 →